MGA’s Alex Brill on The Hill: Virtually Live

MGA founder and CEO Alex Brill recently appeared on The Hill event Virtually Live to discuss how complex generic medical alternatives can impact and potentially enhance the American healthcare system. In this interview, Brill talks with The Hill moderator Steve Clemons about the MGA report outlining the potential savings from accelerating US approval of complex generics. 

Demand for FDA Action Amid Shuffle

“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”

The Evolving Opioid Crisis

As the COVID-19 pandemic has swept across our country and claimed more than 100,000 lives in a few short months, the opioid epidemic, which dates back to at least the early 2000s, has received less attention. But the toll of the opioid crisis in the United States remains enormous by any measure.

Shortened Exclusivity Could Save $31B

“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.”